124 related articles for article (PubMed ID: 29749536)
1. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
He W; Hu H
Oncol Rep; 2018 Jul; 40(1):3-15. PubMed ID: 29749536
[TBL] [Abstract][Full Text] [Related]
2. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
3. BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.
Yan L; Zhang W; Zhang B; Xuan C; Wang D
Tumour Biol; 2017 Apr; 39(4):1010428317698355. PubMed ID: 28443462
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
5. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
[TBL] [Abstract][Full Text] [Related]
6. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
7. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation.
Wang XT; Bao CH; Jia YB; Wang N; Ma W; Liu F; Wang C; Wang JB; Song QX; Cheng YF
Biochem Biophys Res Commun; 2014 Oct; 452(4):945-50. PubMed ID: 25223594
[TBL] [Abstract][Full Text] [Related]
8. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance.
Li M; Zhang X; Zhou WJ; Chen YH; Liu H; Liu L; Yang CM; Qan WB
Acta Pharmacol Sin; 2013 Dec; 34(12):1545-53. PubMed ID: 24241349
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
11. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors.
Saif MW; Takimoto C; Mita M; Banerji U; Lamanna N; Castro J; O'Brien S; Stogard C; Von Hoff D
Clin Cancer Res; 2014 Jan; 20(2):445-55. PubMed ID: 24097863
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.
Dickson MA; Okuno SH; Keohan ML; Maki RG; D'Adamo DR; Akhurst TJ; Antonescu CR; Schwartz GK
Ann Oncol; 2013 Jan; 24(1):252-7. PubMed ID: 22898035
[TBL] [Abstract][Full Text] [Related]
14. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ
Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
17. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.
Ding Y; Adachi H; Katsuno M; Sahashi K; Kondo N; Iida M; Tohnai G; Nakatsuji H; Sobue G
Neuroscience; 2016 Jul; 327():20-31. PubMed ID: 27058144
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
Sbiera S; Kendl S; Weigand I; Sbiera I; Fassnacht M; Kroiss M
Mol Cell Endocrinol; 2019 Jan; 480():36-41. PubMed ID: 30315857
[TBL] [Abstract][Full Text] [Related]
19. BIIB021, an orally available and small-molecule inhibitor of HSP90, activates intrinsic apoptotic pathway in human cervical adenocarcinoma cell line (HeLa).
Güven CM; Özgür A
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7299-7308. PubMed ID: 37606138
[TBL] [Abstract][Full Text] [Related]
20. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
